-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

627.O3.6 627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas

Symposia: Aggressive Lymphomas: Pharmacologic Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Lymphomas, Bispecific Antibody Therapy, Non-Hodgkin lymphoma, Drug development, Clinical Research, B Cell lymphoma, Diseases, Aggressive lymphoma, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Study Population, Human
Monday, December 9, 2024: 4:30 PM-6:00 PM
Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Moderators:
Basem M. William, MD, MRCP(UK), FACP, OhioHealth and James B. Ford, DO, University of Nebraska Medical Center
Disclosures:
William: Morphosys: Consultancy; PPD/Orca: Consultancy; ADC Therapeutics: Consultancy; Guidepoint Global: Consultancy; Genmab: Consultancy; BMS: Consultancy.
This session focuses on novel combination therapies for relapsed or refractory aggressive lymphoma.
4:30 PM

Imran A. Nizamuddin, MD1, Narendranath Epperla, MD, MS2, Mary-Kate Malacek, MD3*, Brad S. Kahl, MD4, Fei Wan, PhD5*, Anne Fischer, BS6*, Chaz Moreno6*, Emily R. King, BA6*, Anna Krivenko2*, Nancy L. Bartlett, MD6 and Neha Mehta-Shah, MD7

1Division of Oncology, Washington University School of Medicine, St. Louis, MO
2The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
3Missouri Baptist Medical Center, St. Louis, MO
4Department of Medicine, Washington University School of Medicine, St. Louis, MO
5Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO
6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
7Siteman Cancer Center, Washington University School of Medicine, Olivette, MO

4:45 PM

Zheng Song1*, Ying Cheng2*, Haiyan Yang3*, Liling Zhang4*, Liqun Zou5*, Ye Guo6*, Junning Cao7, Huiqiang Huang, MD, PhD8*, Zhao Wang9*, Sha Huang10*, Yiqian Fang10*, Jiaoyan Lyu11*, Keshu Zhou, MD12* and Huilai Zhang, MD13

1Tianjin Medical University Cancer Hospital and Institute, Tianjin, China
2Jilin Cancer Hospital, Changchun, China
3Department of Hematology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
4Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
6Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
7Fudan University Shanghai Cancer Center, Shanghai, China
8Sun Yat-sen University, Guangzhou, China
9Beijing Friendship Hospital, Capital Medical University, Beijing, China
10BeiGene (Shanghai) Co, Ltd, Shanghai, China
11BeiGene (Beijing) Co, Ltd, Beijing, China
12Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
13Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

5:00 PM

Catherine S. Diefenbach1, Paolo F. Caimi2, Nakhle S Saba, MD3, Fernando Vargas Madueno, MD4, Mehdi Hamadani, MD5, Luis E. Fayad, MD6, Peter A. Riedell, MD7*, Andrew Gillis-Smith8*, Stephen Simko9*, Victor Orellana-Noia9*, Maria Filippou-Frye9*, Amy V. Kapp9*, James Relf10*, Linda Lundberg11* and Lauren C. Pinter-Brown12*

1Perlmutter Cancer Center at New York University Langone Health, New York, NY
2Cleveland Clinic, Cleveland, OH
3Tulane University School of Medicine, New Orleans, LA
4Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL
5Medical College of Wisconsin, Milwaukee, WI
6Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
7David and Etta Jonas Center for Cellular Therapy, Chicago, IL
8University of Massachusetts Memorial Health, Worcester, MA
9Genentech, Inc., South San Francisco, CA
10Roche Products Ltd, Welwyn Garden City, United Kingdom
11F. Hoffmann-La Roche Ltd, Basel, Switzerland
12University of California, Irvine, CA

5:15 PM

Martin Hutchings1*, Anna Sureda Balari, MD, PhD2, Francesc Bosch3*, Thomas Stauffer Larsen, MD, PhD4*, Paolo Corradini, MD5, Abraham Avigdor, MD6, María José Terol7*, Antonio Rueda Dominguez8*, Antonio Pinto9*, Alan P Skarbnik, MD10, Raul Cordoba, MD, PhD11, Judit Mészáros Joergensen, MD, PhD12*, Pier Luigi Zinzani, MD, PhD13, Ronit Gurion14*, Neta Goldschmidt15*, Wilfred Leung16*, Donghang Li17*, James Relf18*, Maneesh Tandon18*, Gila Sellam19* and Giuseppe Gritti, MD, PhD20*

1Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
3University Hospital Vall d'Hebron, Barcelona, Spain
4Odense University Hospital, Odense, Denmark
5University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
6Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel
7Hospital Clínico Universitario INCLIVA, University of Valencia, Valencia, Spain
8Virgen de la Victoria University Hospital, Málaga, Spain
9National Cancer Institute Fondazione G. Pascale IRCCS, Naples, Italy
10Novant Health Cancer Institute, Charlotte, NC
11Fundación Jiménez Díaz University Hospital, Madrid, Spain
12Aarhus University Hospital, Aarhus, Denmark
13University of Bologna, Bologna, Italy
14Institute of Hematology, Davidoff Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
15Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
16Genentech, Inc., South San Francisco, CA
17Roche (China) Holding Ltd, Shanghai, China
18Roche Products Ltd, Welwyn Garden City, United Kingdom
19F. Hoffmann-La Roche Ltd, Basel, Switzerland
20ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy

5:30 PM

Julio C. Chavez, MD1, Adam J. Olszewski2*, Mariana Bastos-Oreiro3*, Sarit E. Assouline, MD4, Izidore S. Lossos, MD5, Catherine Diefenbach6, Nilanjan Ghosh7*, Dipenkumar Modi, MD8, Waleed Sabry, MD, MSc. PhD, FRCPE9*, Seema Naik, MD10*, Nirav N. Shah, MD11, Ronan Foley, MD, FRCPC12*, Daniel J Hodson, MD-PhD13, Sneha Makadia14*, Song Pham15*, Elicia Penuel14*, Hao Wu14*, Wahib S. Ead14*, Iris To14*, Connie Lee Batlevi14, Michael C. Wei14* and L. Elizabeth Budde16

1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI
3Hospital General Universitario Gregorio Marañón, Madrid, Spain
4Jewish General Hospital, McGill University, Montreal, QC, Canada
5University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL
6Perlmutter Cancer Center at NYU Langone Health, New York, NY
7Levine Cancer Institute/Atrium Health, Charlotte, NC
8Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI
9Saskatoon Cancer Centre, Saskatoon, SK, Canada
10Penn State Cancer Institute, Hershey, PA
11Medical College of Wisconsin, Milwaukee, WI
12Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
13Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
14Genentech, Inc., South San Francisco, CA
15Hoffmann-La Roche Ltd, Mississauga, ON, Canada
16City of Hope National Medical Center, Duarte, CA

5:45 PM

Martin Hutchings, MD, PhD1, Michael J. Dickinson, MBBS, DMedSci2, Giuseppe Gritti, MD, PhD3*, Carmelo Carlo-Stella, MD4, William Townsend5*, Francesc Bosch, MD, PhD6,7, Nancy L. Bartlett, MD8, Guillaume Cartron9*, Herve Ghesquieres, MD, PhD10*, Roch Houot, MD, PhD11*, Harriet S. Walter, MD, PhD, MRCP12*, Fritz Offner, MD, PhD13, Natalie Dimier, PhD14*, Candice Jamois, PharmD15*, Lance Smith16*, Sylvia Herter, PhD17*, Denis Sahin, PhD18*, Abiraj Keelara, PhD19*, Koorosh Korfi, PhD20, Jeremy Gallien19*, Marie-Helene Wasmer15*, Heather Hinton21*, Matt Whayman16*, Isabel Prieto22*, Georgios Kazantzidis15*, Katharina Lechner23* and Franck Morschhauser, MD, PhD24

1Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
2Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3Department of Oncology-Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
4IRCCS Humanitas Research Hospital, Humanitas University, ROZZANO, ITA
5NIHR Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
6Hematology Department, Hospital Universitario Vall d’Hebron, Barcelona, Spain
7Hematology Department, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Spain
8Division of Oncology, Washington University School of Medicine, St. Louis, MO
9CHU Montpellier, Montpellier, FRA
10Department of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France
11CHU Rennes, Univ Rennes, Inserm & EFS, Rennes, France
12University of Leicester and University Hospitals Leicester, Leicester, GBR
13Universitair Ziekenhuis Ghent, Ghent, Belgium
14Roche Innovation Center Welwyn, Roche, Welwyn, GBR
15Pharma Research and Early Development, Roche Innovation Center Basel, Roche, Basel, Switzerland
16Innovation Center Welwyn, Roche, Welwyn, United Kingdom
17Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
18Product Development Oncology and Hematology, Roche Innovation Center Basel, Roche, Basel, Switzerland
19Roche Innovation Center, Basel, Switzerland
20Roche Innovation Center Zurich, Roche, Schlieren, -- Select, Switzerland
21Product Development, Innovation Center Basel, Roche, Basel, Switzerland
22Product Development, Innovation Center Welwyn, Roche, Welwyn, United Kingdom
23Pharma Research and Early Development, Innovation Center Munich, Roche, Penzberg, Germany
24Centre Hospitalier Régional Universitaire de Lille, Lille, France

*signifies non-member of ASH